Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats

Background:  Sorafenib is a standard drug used for advanced hepatocellular carcinoma but is often resistant and toxic. Its combination with epigallo-3-catechin gallate leads to reduced resistance and toxicity but an equally effective anti-angiogenic effect.Therefore, this study aims to assess the an...

Descripción completa

Detalles Bibliográficos
Autores principales: Irawan, Andry, Prabowo, Erik, Riwanto, Ignatius, Atmodjo, Wahyuni Lukita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843086/
https://www.ncbi.nlm.nih.gov/pubmed/36726605
http://dx.doi.org/10.12688/f1000research.109142.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843086/
https://www.ncbi.nlm.nih.gov/pubmed/36726605
http://dx.doi.org/10.12688/f1000research.109142.3

Ejemplares similares